ENDOMETRIAL CANCER RECURRENT

This adverse event was reported 131 times

These drugs are most commonly taken by patients reporting ENDOMETRIAL CANCER RECURRENT:

# Drug Count
0 CARBOPLATIN 31
1 PACLITAXEL 26
2 PACLITAXEL (AIBUMIN-BOUND) 26
3 DOSTARLIMAB 16
4 PEMBROLIZUMAB 16
5 LENVATINIB 10
6 DURVALUMAB 9
7 LEVONORGESTREL 8
8 TRASTUZUMAB 8
9 OLAPARIB 6
See all common drugs associated with ENDOMETRIAL CANCER RECURRENT

ENDOMETRIAL CANCER RECURRENT is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 DOSTARLIMAB 16 0.0064
1 PEGFILGRASTIM-CBQV 1 0.0007
2 DURVALUMAB 9 0.0004
3 APREPITANT 3 0.0004
4 SOTALOL HYDROCHLORIDE TABLES AF 1 0.0004
5 SOTALOL HYDROCHLORIDE TABLETS AF 1 0.0004
6 ADALIMUMAB-AFZB 1 0.0004
7 LENVATINIB 10 0.0003
8 ENASIDENIB MESYLATE 1 0.0003
9 OLAPARIB 6 0.0003
See all drugs enriched for association with ENDOMETRIAL CANCER RECURRENT